Table 1 Socio-demographic and clinical characteristic of solid cancer patients enrolled in the study
|  | Toxicity group (n = 82) | No-toxicity group (n = 96) | Fisher’s exact test (P) | ||
|---|---|---|---|---|---|
n | (%) | n | (%) | ||
Sex | |||||
 Female | 46 | (56.1) | 46 | (47.9) |  |
 Male | 36 | (43.9) | 50 | (52.1) | 0.295 |
Age, years (median, range) | 62 | (52–68) | 64 | (51–68) | 0.511 |
Cancer type | |||||
 Colon | 49 | (59.8) | 66 | (68.8) |  |
 Rectum | 14 | (17.1) | 17 | (17.7) |  |
 Breast | 5 | (6.1) | 5 | (5.2) |  |
 Stomach | 4 | (4.9) | 1 | (1.0) |  |
 Head and neck | 1 | (1.2) | 3 | (3.1) |  |
 Pancreas | 1 | (1.2) | 3 | (3.1) |  |
 Others | 2 | (2.4) | 1 | (1.0) |  |
 Unknown | 6 | (7.3) | 0 | (0.0) | 0.078 |
Chemotherapy | |||||
 Fluoropyrimidines |  |  |  |  |  |
 5-Fluorouracil | 68 | (82.9) | 81 | (84.4) |  |
 Capecitabine | 14 | (17.1) | 15 | (15.6) | 0.840 |
 Monotherapy | 8 | (9.8) | 7 | (7.3) |  |
 Association with oxaliplatin | 18 | (22.0) | 38 | (39.6) |  |
 Association with irinotecan | 38 | (46.3) | 35 | (36.5) |  |
 Association with other drugs | 18 | (22.0) | 16 | (16.7) | 0.091 |
Therapy setting | |||||
 Neo-adjuvant | 5 | (6.1) | 8 | (8.3) |  |
 Adjuvant | 22 | (26.8) | 42 | (43.8) |  |
 First-line or further lines | 55 | (67.1) | 46 | (47.9) | 0.034 |
Max toxicity grade* | |||||
 3 | 50 | (61.0) | – |  |  |
 4 | 32 | (39.0) | – |  |  |